Ajanta Pharma's Q1 FY 2025-26 Quarterly Results

Result Summary

• Ajanta Pharma Ltd reported a 22.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 13.5%.
• Its expenses for the quarter were up by 23.0% QoQ and 17.5% YoY.
• The net profit increased 26.0% QoQ and increased 3.9% YoY.
• The earnings per share (EPS) of Ajanta Pharma Ltd stood at 20.4 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Ajanta Pharma Ltd is a renowned pharmaceutical company primarily engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company operates in various therapeutic segments, including cardiology, dermatology, ophthalmology, and pain management, catering to both domestic and international markets. Known for its robust research and development capabilities, Ajanta Pharma has a significant presence across various regions, with a diversified product portfolio that emphasizes quality and innovation. Recent developments have seen the company focusing on expanding its global footprint and enhancing its production capacities to meet growing demand across its operational segments.

Revenue

During Q1FY26, Ajanta Pharma Ltd reported a total income of ₹1,328.98 crores, marking a notable increase from ₹1,089.58 crores in Q4FY25, which represents a quarter-over-quarter growth of 22.0%. Compared to the same quarter in the previous year, Q1FY25, where the total income was ₹1,171.39 crores, there was a year-over-year increase of 13.5%. This upward trend in revenue reflects the company's ongoing efforts to optimize its sales channels and possibly expand its market reach, although no specific details are provided in the data.

Profitability

The company's profitability metrics for Q1FY26 indicate a profit before tax of ₹331.13 crores, rising from ₹278.04 crores in Q4FY25, showcasing a quarter-over-quarter growth of 19.1%. Compared to Q1FY25, where the profit before tax was ₹322.12 crores, there is a year-over-year increase of 2.8%. The profit after tax for Q1FY26 was ₹255.34 crores, up from ₹202.72 crores in Q4FY25, a QoQ growth of 26.0%. Year-over-year, this represents a 3.9% increase from ₹245.77 crores in Q1FY25. The tax expenses remained relatively stable, with a slight QoQ increase of 0.6% and a YoY decrease of 0.7%.

Operating Metrics

Earnings per share (EPS) for Ajanta Pharma Ltd in Q1FY26 stood at ₹20.40, an increase from ₹16.10 in Q4FY25, reflecting a QoQ growth of 26.7%. Compared to the same quarter in the previous year, where the EPS was ₹19.50, there was a YoY increase of 4.6%. Total expenses for Q1FY26 were ₹997.85 crores, up from ₹811.54 crores in Q4FY25, indicating a 23.0% QoQ increase. Compared to Q1FY25, with expenses of ₹849.27 crores, the YoY increase was 17.5%. This data highlights a significant rise in both revenue and expenses, suggesting operational changes or expansions during this period.